Status:
TERMINATED
Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer
Lead Sponsor:
Genmab
Conditions:
Non Small Cell Lung Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
The purpose of the study is to investigate if treatment with zalutumumab in combination with chemotherapy and radiotherapy (chemo-radiation) will lead to a prolonged life in patients with lung cancer ...
Detailed Description
Originally the study was planned as Part 1A, Part 1B and Part 2. Part 1A was one arm with zalatumumab fixed dose 8 mg/kg. Part 1B was planned as zalutumumab dose-titration and Part 2 adding a comparat...
Eligibility Criteria
Inclusion
- NSCLC stage IIIA-IIIB
- Performance status 0 or 1 (Zubrod or WHO Scale)
Exclusion
- Evidence of metastases either in a separate lobe of the lung, or extra thoracic
- Patients with high risk of radiation pneumonitis and or compromised lung function
- Estimated life expectancy of less than 3 months
- Prior chemotherapy for lung cancer
- Prior radiotherapy to the chest
- Prior surgery with curative intent for lung cancer
Key Trial Info
Start Date :
April 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
13 Patients enrolled
Trial Details
Trial ID
NCT00460551
Start Date
April 1 2007
End Date
October 1 2008
Last Update
December 6 2011
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Towson, Maryland, United States, 21204
2
Providence Portland Medical Center
Portland, Oregon, United States, 97213-2967
3
UZ Gent
Ghent, Belgium, 9000
4
CHR La Citadelle
Liège, Belgium, 4000